Severe community-acquired pneumonia: The search for the diagnostic holy grail continues

Critical Care Medicine

Volumn 39, Issue 10, 2011, Pages 2354-2355

  Wunderink, Richard G ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

biomarkers; community acquired pneumonia; pneumonia; procalcitonin

Indexed keywords

CEPHALOSPORIN; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

ANTIBIOTIC THERAPY; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; EDITORIAL; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE; LENGTH OF STAY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR;

COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTENSIVE CARE UNITS; MALE; PNEUMONIA;

EID: 80052978199     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31822a5847     Document Type: Editorial

References (19)

1. Waterer GW, Rello J, Wunderink RG: Management of community-acquired pneumonia in adults. Am J Respir Crit Care Med 2011; 183:157-164
2. Mandell LA, Wunderink RG, Anzueto A, et al: Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of communityacquired pneumonia in adults. Clin Infect Dis 2007; 44(Suppl):S27-S72 (Pubitemid 46290553)
3. Hook EW 3rd, Horton CA, Schaberg DR: Failure of intensive care unit support to influence mortality from pneumococcal bacteremia. JAMA 1983; 249:1055-1057 (Pubitemid 13137431)
4. Renaud B, Santin A, Coma E, et al: Association between timing of intensive care unit admission and outcomes for emergency department patients with community-acquired pneumonia. Crit Care Med 2009; 37:2867-2874
5. Restrepo MI, Mortensen EM, Rello J, Brody J, et al: Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest 2010; 137:552-557
6. Angus DC, Marrie TJ, Obrosky DS, et al: Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med 2002; 166:717-723 (Pubitemid 34971856)
7. Liapikou A, Ferrer M, Polverino E, et al: Severe community-acquired pneumonia: Validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. Clin Infect Dis 2009; 48:377-385
8. Brown SM, Jones BE, Jephson AR, et al: Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia. Crit Care Med 2009; 37: 3010-3016
9. Phua J, See KC, Chan YH, et al: Validation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia. Thorax 2009; 64:598-603
10. Wunderink RG, Laterre PF, Francois B, et al: Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: A randomized trial. Am J Respir Crit Care Med 2011; 183:1561-1568
11. Charles PG, Wolfe R, Whitby M, et al: SMARTCOP: A tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008; 47:375-384 (Pubitemid 352009359)
12. Ramirez P, Ferrer M, Martí V, et al: Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. Crit Care Med 2011; 39:2211-2217
13. Renaud B, Labarere J, Coma E, et al: Risk stratification of early admission to the intensive care unit of patients with no major criteria of severe community-acquired pneumonia: Development of an international prediction rule. Crit Care 2009; 13:R54
14. Espana PP, Capelastegui A, Gorordo I, et al: Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med 2006; 174:1249-1256 (Pubitemid 44924826)
15. Fekade D, Knox K, Hussein K, et al: Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha. N Engl J Med 1996; 335:311-315 (Pubitemid 26362378)
16. Laterre PF, Garber G, Levy H, et al: Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study. Crit Care Med 2005; 33:952-961 (Pubitemid 40638163)
17. Laterre PF, Opal SM, Abraham E, et al: A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia. Crit Care 2009; 13:R36
18. Querol-Ribelles JM, Tenias JM, Grau E, et al: Plasma D-dimer levels correlate with outcomes in patients with community-acquired pneumonia. Chest 2004; 126:1087-1092 (Pubitemid 39391236)
19. Rello J, Lisboa T, Lujan M, et al: Severity of pneumococcal pneumonia associated with genomic bacterial load. Chest 2009; 136: 832-840